Free Trial
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Rezolute, Inc. stock logo
RZLT
Rezolute
$4.51
+12.5%		$4.49
$1.07
▼
$11.46
$435.72M0.532.22 million shs2.66 million shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Rezolute, Inc. stock logo
RZLT
Rezolute
0.00%+2.82%-12.45%-18.66%-55.93%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Rezolute, Inc. stock logo
RZLT
Rezolute
$4.51
+12.5%		$4.49
$1.07
▼
$11.46
$435.72M0.532.22 million shs2.66 million shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Rezolute, Inc. stock logo
RZLT
Rezolute
0.00%+2.82%-12.45%-18.66%-55.93%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Rezolute, Inc. stock logo
RZLT
Rezolute
2.71
Moderate Buy$10.44131.43% Upside

Current Analyst Ratings Breakdown

Latest RZLT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/30/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
Lake Street Capital logo
Lake Street Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$9.00
9/29/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
Craig Hallum logo
Craig Hallum
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Buy$4.00 ➝ $7.00
9/25/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
HSBC Holdings plc logo
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeBuy
9/25/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform
9/25/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$5.00 ➝ $10.00
8/14/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
7/30/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/17/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/16/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
(Data available from 10/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Rezolute, Inc. stock logo
RZLT
Rezolute
N/AN/AN/AN/A$1.05 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Rezolute, Inc. stock logo
RZLT
Rezolute
-$77.59M-$0.76N/AN/AN/AN/A-62.99%-57.94%11/5/2026 (Estimated)

Latest RZLT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/24/2026Q4 2026
Rezolute, Inc. stock logo
RZLT
Rezolute
-$0.1479-$0.20-$0.0522-$0.20N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Rezolute, Inc. stock logo
RZLT
Rezolute
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Rezolute, Inc. stock logo
RZLT
Rezolute
N/A
9.68
9.68

Institutional Ownership

CompanyInstitutional Ownership
Rezolute, Inc. stock logo
RZLT
Rezolute
82.97%

Insider Ownership

CompanyInsider Ownership
Rezolute, Inc. stock logo
RZLT
Rezolute
14.78%
CompanyEmployeesShares OutstandingFree FloatOptionable
Rezolute, Inc. stock logo
RZLT
Rezolute
5896.72 million82.43 millionOptionable

Recent News About These Companies

Rezolute Says FDA Recommends Pre-BLA Meeting for Congenital Hyperinsulinism Treatment
 |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/rezolute-says-fda-recommends-pre-120435720.html
Rezolute gets FDA nod for pre-BLA meeting despite phase 3 miss — retail expects huge rerating
 |  msn.comhttps://www.msn.com/en-in/news/other/rezolute-gets-fda-nod-for-pre-bla-meeting-despite-phase-3-miss-retail-expects-huge-rerating/ar-AA2dBtbf
Rezolute (NASDAQ:RZLT) Stock Sees Unusually High Call Option Buying
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/options-rezolute-nasdaq-rzlt-stock-sees-unusually-high-call-option-buying-2026-10-05/
Rezolute Prepares For Potential BLA Filing Of Ersodetug In Congenital HI
October 5 at 8:21 AM  |  rttnews.comhttps://www.rttnews.com/3696465/rezolute-prepares-for-potential-bla-filing-of-ersodetug-in-congenital-hi.aspx
Rezolute receives FDA guidance for ersodetug pre-BLA meeting
October 5 at 8:21 AM  |  grafa.comG
FDA Recommends Next Regulatory Step For Rezolute's Ersodetug;Stock Up
October 5 at 8:21 AM  |  rttnews.comhttps://www.rttnews.com/3696473/fda-recommends-next-regulatory-step-for-rezolute-s-ersodetug-stock-up.aspx
Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism
October 5 at 7:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/05/3374399/0/en/rezolute-announces-fda-recommendation-to-hold-a-pre-bla-meeting-as-a-precursor-to-submitting-a-biologics-license-application-bla-for-congenital-hyperinsulinism.html
Rezolute consensus price target increased by 18.70% to $9.28
October 2 at 1:57 PM  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/rezolute-consensus-price-target-increased-by-18-70-to-9-28/ar-AA2dqXbo
Lake Street Capital Initiates Coverage on Rezolute (NASDAQ:RZLT)
October 2 at 1:54 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31076735
Rezolute (NASDAQ:RZLT) Raised to "Buy" at Craig Hallum
October 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31072106
Rezolute (NASDAQ:RZLT) Coverage Initiated by Analysts at Lake Street Capital
September 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-rezolute-nasdaq-rzlt-coverage-initiated-by-analysts-at-lake-street-capital-2026-09-30/
Craig-Hallum upgrades Rezolute to buy from hold
September 29, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/craig-hallum-upgrades-rezolute-to-buy-from-hold/ar-AA2dcCjD
Rezolute (NASDAQ:RZLT) Upgraded at Craig Hallum
September 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-rezolute-nasdaq-rzlt-upgraded-at-craig-hallum-2026-09-29/
Rezolute Stock Earnings Estimates Decreased by HC Wainwright
September 29, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31063704
HC Wainwright Estimates Rezolute's Q1 Earnings (NASDAQ:RZLT)
September 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-hc-wainwright-estimates-rezolutes-q1-earnings-nasdaq-rzlt-2026-09-29/
Rezolute (NASDAQ:RZLT) Stock Gets Price Target Increase from HC Wainwright
September 27, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31053914
Rezolute Posts Narrower Loss In Q4; Expects Phase 3 Ersodetug Topline Data By 2026 End
September 26, 2026  |  rttnews.comhttps://www.rttnews.com/3693906/rezolute-posts-narrower-loss-in-q4-expects-phase-3-ersodetug-topline-data-by-2026-end.aspx
Rezolute (NASDAQ:RZLT) Given New $10.00 Price Target at HC Wainwright
September 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-rezolute-nasdaq-rzlt-given-new-1000-price-target-at-hc-wainwright-2026-09-25/
Rezolute, Inc.: Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update
September 25, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-09/69675562-rezolute-inc-rezolute-reports-fourth-quarter-and-full-year-fiscal-2026-financial-results-and-provides-business-update-399.htm
Rezolute Fiscal Q4 Loss Narrows
September 24, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/rezolute-fiscal-q4-loss-narrows-201830711.html
Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update
September 24, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/24/3368741/0/en/rezolute-reports-fourth-quarter-and-full-year-fiscal-2026-financial-results-and-provides-business-update.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Rezolute stock logo

Rezolute NASDAQ:RZLT

$4.51 +0.50 (+12.54%)
As of 03:15 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas